Moderna curbing investments in vaccine trials due to US backlash, CEO tells Bloomberg TV

Core Viewpoint - Moderna will not invest in new late-stage vaccine trials due to increasing opposition to immunizations from U.S. officials, as stated by CEO Stephane Bancel in an interview with Bloomberg TV [1] Company Summary - Moderna's decision reflects a strategic shift in response to the current political and public sentiment regarding vaccinations in the U.S. [1]